Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jarisch

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
The Prostate|March 22, 2000
Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patientsG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
The Prostate|March 22, 2000
Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patientsG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 1